After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

A consumer-driven weight loss market could put pharma at greater risk if a recession hits; the continued turmoil at FDA and other HHS agencies magnifies the uncertainty facing the industry; Lilly ...

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...

One of the great things about equity markets is that you don't need a fortune to get started. Though strong companies that ...

Its investigational medicine for metabolic dysfunction-associated steatohepatitis (MASH), VK2809 ... Prosper Junior Bakiny has positions in Eli Lilly, Exelixis, Novo Nordisk, and Viking Therapeutics.

Eli Lilly (LLY) stock gains as Goldman Sachs upgrades it to Buy from Neutral citing the company's leadership position in the ...

Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic ...

A Lilly statement said, "We will continue to take action to stop these illegal actors and urgently call on regulators and law ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...